Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mite allergen-specific immunotherapy
- Development stage
- Unknown
- Lead developer
- Renji Hospital
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Mite allergen-specific immunotherapy (AIT) is a disease-modifying treatment for respiratory allergic diseases, such as bronchial asthma and allergic rhinitis, triggered by house dust mites (HDM). The therapy involves the repeated administration of specific mite allergens (typically from *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*) to the patient. This process aims to induce immunological tolerance by modulating the T-cell response (shifting from Th2 to Th1/Treg), increasing the production of allergen-specific IgG4 antibodies, and reducing IgE-mediated inflammation. It can be delivered via subcutaneous injection (SCIT) or sublingual drops/tablets (SLIT). In the context of the Renji Hospital study, it is being evaluated for its impact on hyperactivity symptoms in children with respiratory allergies.
- Other names
- house dust mite allergen immunotherapyHDM-AITmite-specific immunotherapymite allergen-specific subcutaneous immunotherapy
02
Targets
House dust mite–specific B-cell receptorTCR (T cell antigen receptor complex)
Beyond the preview
Go deeper on mite allergen-specific immunotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mite allergen-specific immunotherapy.